The Value of Prostate-Specific Antigen-Related Indexes and Imaging Screening in the Diagnosis of Prostate Cancer

被引:9
|
作者
Bai, Xiaojing [1 ,2 ]
Jiang, Yumei [1 ,2 ]
Zhang, Xinwei [1 ,2 ]
Wang, Meiyu [3 ]
Tian, Juanhua [1 ]
Mu, Lijun [1 ]
Du, Yuefeng [1 ,2 ]
机构
[1] Xi An Jiao Tong Univ, Dept Urol, Affiliated Hosp 1, 277 Western Yanta Rd, Xian 710061, Shaanxi, Peoples R China
[2] Minist Educ, Oncol Res Lab, Key Lab Environm & Genes Related Dis, Xian 710061, Shaanxi, Peoples R China
[3] Xi An Jiao Tong Univ, Dept Imaging, Affiliated Hosp 1, Xian 710061, Shaanxi, Peoples R China
来源
CANCER MANAGEMENT AND RESEARCH | 2020年 / 12卷
基金
中国国家自然科学基金;
关键词
total prostate-specific antigen; free prostate-specific antigen; prostate-specific antigen density; prostate cancer; benign prostatic hyperplasia; FREE ELECTROCHEMICAL IMMUNOSENSOR; DIGITAL RECTAL EXAMINATION; ULTRASOUND-GUIDED BIOPSY; MULTI-PARAMETRIC MRI; MAGNETIC-RESONANCE; HIGH-RISK; NG/ML; PSA; MEN; COMPLICATIONS;
D O I
10.2147/CMAR.S257769
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Objective: The aim of this study was to explore the value of the prostate-specific antigen (PSA) levels, the ratio of free PSA to total PSA (fPSA/TPSA), the PSA density (PSAD), digital rectal examination (DRE), transrectal prostate ultrasound (TRUS), and multiparameter MRI (MP-MRI) in the differential diagnosis of benign prostatic hyperplasia (BPH) and prostate cancer (PCa). Methods: From February 2016 to September 2019, data from 620 patients who underwent systematic transrectal ultrasound-guided prostate biopsy (STURS-PB) in our hospital were retrospectively collected, including the PSA levels, the fPSA/TPSA ratio, the PSAD, DRE, TRUS, MP-MRI, prostate volume, and other clinical data. Results: Among the 620 patients, 249 patients were in the PCa group, and 371 patients in the BPH group. The positive puncture rate was 40.16%. The positive predictive values of DRE, TRUS, mpMRI, and TPSA levels for PCa were 39.91%, 39.38%, 64.14%, and 41.57%, respectively; the sensitivity of these parameters was 37.35%, 51.41%, 74.69%, and 57.43%, respectively; and the specificity of these parameters was 62.26%, 46.90%, 71.97%, and 45.82%, respectively. When the TPSA concentration was in the range of 4-20 ng/mL, the positive puncture rate of STURS-PB was 23.18%, with a high rate of misdiagnosis. When the TPSA concentration was in the range of 4-20 ng/mL, the fPSA/ TPSA ratio was 0.15, the PSAD was 0.16, the comprehensive evaluation of PCa was optimal (the sensitivity of these parameters was 88.85% and 84.09%, respectively; the specificity was 80.17% and 67.29%, respectively; the positive predictive value was 57.41% and 51.39%, respectively). When the TPSA concentration >4 ng/mL, the fPSA/TPSA ratio <= 0.15 and the PSAD >= 0.16, the sensitivity, specificity, and correctness index of the PCa and BPH diagnosis were 80.54%, 82.75%, and 67.07%, respectively. Conclusion: When using DRE, TRUS, and MP-MRI to screen for PCa, MP-MRI has a relatively high sensitivity and specificity. Using these three thresholds (TPSA >4 ng/mL combined with an fPSA/TPSA ratio <= 0.15 and a PSAD >= 0.16) is significantly better than using TPSA levels alone for the differential diagnosis of PCa and BPH.
引用
收藏
页码:6821 / 6826
页数:6
相关论文
共 50 条
  • [1] Diagnostic value of prostate-specific antigen-related parameters in discriminating prostate cancer
    Matsuyama, H
    Baba, Y
    Yamakawa, G
    Yamamoto, N
    Naito, K
    INTERNATIONAL JOURNAL OF UROLOGY, 2000, 7 (11) : 409 - 414
  • [2] Prostate-specific antigen-based prostate cancer screening: Past and future
    Alberts, Arnout R.
    Schoots, Ivo G.
    Roobol, Monique J.
    INTERNATIONAL JOURNAL OF UROLOGY, 2015, 22 (06) : 524 - 532
  • [3] Prostate-specific Antigen Testing and Prostate Cancer Screening
    Djavan, Bob
    Eckersberger, Elisabeth
    Finkelstein, Julia
    Sadri, Helen
    Taneja, Samir S.
    Lepor, Herbert
    PRIMARY CARE, 2010, 37 (03): : 441 - +
  • [4] The Role of Prostate-Specific Antigen in Prostate Cancer Screening
    Constantin, Traian Vasile
    Madan, Victor Lucian
    Constantin, Maria-Magdalena
    Morariu, Silviu-Horia
    Braticevici, Bogdan
    REVISTA ROMANA DE MEDICINA DE LABORATOR, 2014, 22 (02): : 275 - 281
  • [5] On the use of prostate-specific antigen for screening of prostate cancer in European Randomised Study for Screening of Prostate Cancer
    Bangma, Chris H.
    van Schaik, Ron H.
    Blijenberg, Bert G.
    Roobol, Monique J.
    Lilja, Hans
    Stenman, Ulf-Hakan
    EUROPEAN JOURNAL OF CANCER, 2010, 46 (17) : 3109 - 3119
  • [6] Defining the optimal prostate-specific antigen threshold for the diagnosis of prostate cancer
    Schroeder, Fritz H.
    Roobol, Monique J.
    CURRENT OPINION IN UROLOGY, 2009, 19 (03) : 227 - 231
  • [7] Optimal prostate-specific antigen screening interval for prostate cancer
    Kobayashi, D.
    Takahashi, O.
    Fukui, T.
    Glasziou, P. P.
    ANNALS OF ONCOLOGY, 2012, 23 (05) : 1250 - 1253
  • [8] Prospective evaluation of prostate cancer detection by prostate-specific antigen-related parameters
    Egawa, S
    Suyama, K
    Takashima, R
    Mizoguchi, H
    Kuwao, S
    Baba, S
    INTERNATIONAL JOURNAL OF UROLOGY, 1999, 6 (10) : 493 - 501
  • [9] Body mass index in relation to prostate-specific antigen-related parameters
    Lin, Dandan
    Liu, Ting
    Chen, Luling
    Chen, Zongtao
    BMC UROLOGY, 2021, 21 (01)
  • [10] Analysis of the predictive value of the prostate-specific antigen-to-neutrophil ratio for the diagnosis of prostate cancer
    Chen, Yuxuan
    Yan, Haisheng
    Xu, Yaoqin
    Chen, Kexin
    Yang, Runqin
    Yang, Jiali
    Zhu, Ruian
    Lin, Rui
    Wang, Jiang
    Liu, Jie
    Gao, Pingsheng
    Pang, Lei
    Wang, Lexin
    DISCOVER ONCOLOGY, 2025, 16 (01)